Editors ’ Picks

Loss-of-function mutations in IL36RN, which encodes the IL-36 receptor antagonist, have been identified in some patients with generalized pustular psoriasis, implicating this pathway in pathogenesis. In a phase 1 proof-of-concept study involving seven patients, Bachelez and colleagues found that a single intravenous dose of a monoclonal antibody (BI 655130) against the IL-36 receptor reduced the severity of generalized pustular psoriasis in all patients over a 20-week period. Pustules were completely cleared in six patients by week 2, and the inflammatory marker C-reactive protein was dramatically reduced as well.

Source: Journal of Investigative Dermatology - May 22, 2019 Category: Dermatology Tags: Editorial Source Type: research